ReviewBioMed research international2020
Current Progress on Assessing the Prognosis for Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis.
Review in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- BrainEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- Anti-NMDA Receptor Encephalitis Associated with Ovarian Teratoma: A Comprehensive Review.Biomedicines · 2026Review
- Delayed Recognition of Anti-NMDAR Encephalitis Mimicking Primary Psychiatric Illness: A Case Report.Clinical case reports · 2026Article
- Efgartigimod as a salvage therapy for anti-NMDAR encephalitis patients after first-line treatment failure: a case series.Frontiers in neurology · 2026Article
- Assessment of clinical prognosis in autoimmune encephalitis: Girona score.Frontiers in psychiatry · 2025Article
- Late relapse of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: a case report.Journal of medical case reports · 2024Article
- Aberrant functional hubs and related networks attributed to cognitive impairment in patients with anti‑N‑methyl‑D‑aspartate receptor encephalitis.Biomedical reports · 2024Article
- Predictors of mortality and poor outcome for patients with severe infectious encephalitis in the intensive care unit: a cross-sectional study.BMC infectious diseases · 2024Article
- Clinical characteristics of autoimmune encephalitis with co-existence of multiple anti-neuronal antibodies.BMC neurology · 2024Article
- Hypometabolism of the left middle/medial frontal lobe on FDG-PET in anti-NMDA receptor encephalitis: Comparison with MRI and EEG findings.CNS neuroscience & therapeutics · 2023Article
- Systematic review: clinical characteristics of anti-N-methyl-D-aspartate receptor encephalitis.Frontiers in human neuroscience · 2023Review
- Case report: Anti-NMDA receptor encephalitis manifesting as rapid weight loss and abnormal movement disorders with alternating unilateral ptosis and contralateral limb tremor.Frontiers in immunology · 2022Article
- Clinical Study of Autonomic Dysfunction in Patients With Anti-NMDA Receptor Encephalitis.Frontiers in neurology · 2021Article
- Neuronal Surface Antibody-Medicated Autoimmune Encephalitis (Limbic Encephalitis) in China: A Multiple-Center, Retrospective Study.Frontiers in immunology · 2021Article
- Anti-N-methyl-d-aspartate Receptor Encephalitis Related Sinus Node Dysfunction and the Lock-Step Phenomenon.American journal of medical case reports · 2020Article
- Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review.Multiple sclerosis journal - experimental, translational and clinicalArticle
- NMDA Receptor Encephalitis with Significant Autonomic Instability and PRES like MR Images.Annals of Indian Academy of NeurologyArticle
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Decrease in Blood Flow in Cerebellum.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common antineuronal antibody encephalitis in autoimmune encephalitis found at present. It has complex clinical manifestations such as psychiatric and behavioral abnormalities, seizures, movement disorders, consciousness, and autonomic dysfunction. The relationship between those manifestations and prognosis is unclear. Electroencephalography (EEG) is gradually becoming useful in the evaluation of the prognosis of anti-NMDAR encephalitis patients, while imaging and antibody testing have a limited prognostic value. Starting the patients on adequate treatments (such as immunotherapy) in a timely fashion has a positive impact on their prognosis. Nevertheless, research on the prognosis of anti-NMDAR encephalitis remains scarce. Here, we review the current advances of prognosis-related research from the clinical manifestations of the disease and auxiliary examinations such as EEG, magnetic resonance imaging (MRI), 18F fluorodeoxyglucose positron emission tomography (FDG-PET), and antibody measurement. In addition, we also discuss the impact of different treatment options on prognosis. In-depth research on the prognosis of patients with anti-NMDAR encephalitis will contribute to a better understanding of this disease, leading to better treatments options and, ultimately, a better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.